nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—NTRK1—peripheral nervous system neoplasm	0.387	0.877	CbGaD
Imatinib—ABCB1—peripheral nervous system neoplasm	0.0542	0.123	CbGaD
Imatinib—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0279	0.0935	CbGbCtD
Imatinib—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0194	0.0648	CbGbCtD
Imatinib—CYP3A7—Tretinoin—peripheral nervous system neoplasm	0.0192	0.0642	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Tretinoin—peripheral nervous system neoplasm	0.0192	0.0642	CbGbCtD
Imatinib—SLC22A2—Cisplatin—peripheral nervous system neoplasm	0.0151	0.0504	CbGbCtD
Imatinib—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0144	0.0482	CbGbCtD
Imatinib—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0119	0.0399	CbGbCtD
Imatinib—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0115	0.0386	CbGbCtD
Imatinib—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0111	0.0372	CbGbCtD
Imatinib—ABCG2—Etoposide—peripheral nervous system neoplasm	0.0109	0.0366	CbGbCtD
Imatinib—PTGS1—Etoposide—peripheral nervous system neoplasm	0.0101	0.0338	CbGbCtD
Imatinib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0101	0.0337	CbGbCtD
Imatinib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0101	0.0337	CbGbCtD
Imatinib—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.00965	0.0323	CbGbCtD
Imatinib—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.00921	0.0308	CbGbCtD
Imatinib—CYP3A7—Vincristine—peripheral nervous system neoplasm	0.00881	0.0295	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Vincristine—peripheral nervous system neoplasm	0.00881	0.0295	CbGbCtD
Imatinib—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.00746	0.025	CbGbCtD
Imatinib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.00698	0.0234	CbGbCtD
Imatinib—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.00661	0.0221	CbGbCtD
Imatinib—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.00606	0.0203	CbGbCtD
Imatinib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.00604	0.0202	CbGbCtD
Imatinib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00561	0.0188	CbGbCtD
Imatinib—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.00451	0.0151	CbGbCtD
Imatinib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0043	0.0144	CbGbCtD
Imatinib—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.00413	0.0138	CbGbCtD
Imatinib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00401	0.0134	CbGbCtD
Imatinib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00394	0.0132	CbGbCtD
Imatinib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00269	0.009	CbGbCtD
Imatinib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00258	0.00862	CbGbCtD
Imatinib—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00253	0.00848	CbGbCtD
Imatinib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00236	0.0079	CbGbCtD
Imatinib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00161	0.00539	CbGbCtD
Imatinib—NTRK1—trigeminal ganglion—peripheral nervous system neoplasm	0.00134	0.0678	CbGeAlD
Imatinib—ABCA3—trigeminal ganglion—peripheral nervous system neoplasm	0.00106	0.0536	CbGeAlD
Imatinib—ABCA3—parotid gland—peripheral nervous system neoplasm	0.001	0.0505	CbGeAlD
Imatinib—DDR1—trigeminal ganglion—peripheral nervous system neoplasm	0.000978	0.0494	CbGeAlD
Imatinib—DDR1—parotid gland—peripheral nervous system neoplasm	0.000923	0.0466	CbGeAlD
Imatinib—CA1—nerve—peripheral nervous system neoplasm	0.000667	0.0337	CbGeAlD
Imatinib—SLC22A1—ganglion—peripheral nervous system neoplasm	0.000604	0.0305	CbGeAlD
Imatinib—PIP4K2C—trigeminal ganglion—peripheral nervous system neoplasm	0.000604	0.0305	CbGeAlD
Imatinib—CA6—parotid gland—peripheral nervous system neoplasm	0.000574	0.029	CbGeAlD
Imatinib—PIP4K2C—parotid gland—peripheral nervous system neoplasm	0.00057	0.0288	CbGeAlD
Imatinib—CA3—parotid gland—peripheral nervous system neoplasm	0.000544	0.0275	CbGeAlD
Imatinib—LCK—trigeminal ganglion—peripheral nervous system neoplasm	0.000536	0.0271	CbGeAlD
Imatinib—ABCA3—cerebellum—peripheral nervous system neoplasm	0.000463	0.0234	CbGeAlD
Imatinib—NQO2—trigeminal ganglion—peripheral nervous system neoplasm	0.000443	0.0224	CbGeAlD
Imatinib—DDR1—cerebellum—peripheral nervous system neoplasm	0.000427	0.0216	CbGeAlD
Imatinib—SLC22A2—trigeminal ganglion—peripheral nervous system neoplasm	0.00042	0.0212	CbGeAlD
Imatinib—NQO2—parotid gland—peripheral nervous system neoplasm	0.000418	0.0211	CbGeAlD
Imatinib—NQO2—brainstem—peripheral nervous system neoplasm	0.000392	0.0198	CbGeAlD
Imatinib—CSF1R—trigeminal ganglion—peripheral nervous system neoplasm	0.000389	0.0197	CbGeAlD
Imatinib—SLC47A1—trigeminal ganglion—peripheral nervous system neoplasm	0.000356	0.018	CbGeAlD
Imatinib—KIT—trigeminal ganglion—peripheral nervous system neoplasm	0.000354	0.0179	CbGeAlD
Imatinib—PDGFRB—trigeminal ganglion—peripheral nervous system neoplasm	0.000345	0.0175	CbGeAlD
Imatinib—ABL1—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000334	0.173	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000334	0.173	CbGdCrCtD
Imatinib—ABL1—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000334	0.173	CbGdCrCtD
Imatinib—KIT—parotid gland—peripheral nervous system neoplasm	0.000334	0.0169	CbGeAlD
Imatinib—PTGS1—ganglion—peripheral nervous system neoplasm	0.00033	0.0167	CbGeAlD
Imatinib—PDGFRB—parotid gland—peripheral nervous system neoplasm	0.000326	0.0165	CbGeAlD
Imatinib—Ponatinib—ABCB1—peripheral nervous system neoplasm	0.000325	0.575	CrCbGaD
Imatinib—SLC47A1—brainstem—peripheral nervous system neoplasm	0.000315	0.0159	CbGeAlD
Imatinib—KIT—brainstem—peripheral nervous system neoplasm	0.000313	0.0158	CbGeAlD
Imatinib—ABL1—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000309	0.16	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.000309	0.16	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.000309	0.16	CbGdCrCtD
Imatinib—ABL1—trigeminal ganglion—peripheral nervous system neoplasm	0.000308	0.0156	CbGeAlD
Imatinib—ABL1—parotid gland—peripheral nervous system neoplasm	0.00029	0.0147	CbGeAlD
Imatinib—ABL2—cerebellum—peripheral nervous system neoplasm	0.000278	0.0141	CbGeAlD
Imatinib—CA7—cerebellum—peripheral nervous system neoplasm	0.000274	0.0139	CbGeAlD
Imatinib—ABL1—brainstem—peripheral nervous system neoplasm	0.000272	0.0138	CbGeAlD
Imatinib—PIP4K2C—cerebellum—peripheral nervous system neoplasm	0.000263	0.0133	CbGeAlD
Imatinib—CA9—cerebellum—peripheral nervous system neoplasm	0.000241	0.0122	CbGeAlD
Imatinib—Nilotinib—ABCB1—peripheral nervous system neoplasm	0.00024	0.425	CrCbGaD
Imatinib—CA14—cerebellum—peripheral nervous system neoplasm	0.000228	0.0115	CbGeAlD
Imatinib—CA2—trigeminal ganglion—peripheral nervous system neoplasm	0.00021	0.0106	CbGeAlD
Imatinib—CA2—parotid gland—peripheral nervous system neoplasm	0.000198	0.00999	CbGeAlD
Imatinib—ABCG2—trigeminal ganglion—peripheral nervous system neoplasm	0.000194	0.00981	CbGeAlD
Imatinib—NQO2—cerebellum—peripheral nervous system neoplasm	0.000193	0.00978	CbGeAlD
Imatinib—PDGFRA—cerebellum—peripheral nervous system neoplasm	0.000193	0.00975	CbGeAlD
Imatinib—CA2—brainstem—peripheral nervous system neoplasm	0.000186	0.00937	CbGeAlD
Imatinib—ABCG2—parotid gland—peripheral nervous system neoplasm	0.000183	0.00925	CbGeAlD
Imatinib—CSF1R—cerebellum—peripheral nervous system neoplasm	0.00017	0.00859	CbGeAlD
Imatinib—SLC47A1—cerebellum—peripheral nervous system neoplasm	0.000155	0.00784	CbGeAlD
Imatinib—KIT—cerebellum—peripheral nervous system neoplasm	0.000154	0.0078	CbGeAlD
Imatinib—PDGFRB—cerebellum—peripheral nervous system neoplasm	0.000151	0.00761	CbGeAlD
Imatinib—ABL1—cerebellum—peripheral nervous system neoplasm	0.000134	0.00679	CbGeAlD
Imatinib—CYP2D6—brainstem—peripheral nervous system neoplasm	0.000118	0.00595	CbGeAlD
Imatinib—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	9.57e-05	0.00484	CbGeAlD
Imatinib—CA2—cerebellum—peripheral nervous system neoplasm	9.15e-05	0.00462	CbGeAlD
Imatinib—ABCG2—cerebellum—peripheral nervous system neoplasm	8.47e-05	0.00428	CbGeAlD
Imatinib—CYP2D6—cerebellum—peripheral nervous system neoplasm	5.81e-05	0.00293	CbGeAlD
Imatinib—ABCB1—cerebellum—peripheral nervous system neoplasm	4.18e-05	0.00211	CbGeAlD
Imatinib—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	3.59e-05	0.000214	CcSEcCtD
Imatinib—Rash—Dactinomycin—peripheral nervous system neoplasm	3.58e-05	0.000214	CcSEcCtD
Imatinib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	3.58e-05	0.000214	CcSEcCtD
Imatinib—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	3.56e-05	0.000213	CcSEcCtD
Imatinib—Renal failure—Epirubicin—peripheral nervous system neoplasm	3.55e-05	0.000212	CcSEcCtD
Imatinib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	3.55e-05	0.000212	CcSEcCtD
Imatinib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	3.55e-05	0.000212	CcSEcCtD
Imatinib—Fatigue—Etoposide—peripheral nervous system neoplasm	3.55e-05	0.000212	CcSEcCtD
Imatinib—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	3.54e-05	0.000212	CcSEcCtD
Imatinib—Jaundice—Epirubicin—peripheral nervous system neoplasm	3.52e-05	0.000211	CcSEcCtD
Imatinib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	3.52e-05	0.000211	CcSEcCtD
Imatinib—Constipation—Etoposide—peripheral nervous system neoplasm	3.52e-05	0.00021	CcSEcCtD
Imatinib—Pain—Etoposide—peripheral nervous system neoplasm	3.52e-05	0.00021	CcSEcCtD
Imatinib—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	3.52e-05	0.00021	CcSEcCtD
Imatinib—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	3.52e-05	0.00021	CcSEcCtD
Imatinib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	3.51e-05	0.00021	CcSEcCtD
Imatinib—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	3.49e-05	0.000208	CcSEcCtD
Imatinib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	3.49e-05	0.000208	CcSEcCtD
Imatinib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	3.48e-05	0.000208	CcSEcCtD
Imatinib—Sweating—Epirubicin—peripheral nervous system neoplasm	3.47e-05	0.000207	CcSEcCtD
Imatinib—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	3.47e-05	0.000207	CcSEcCtD
Imatinib—Haematuria—Epirubicin—peripheral nervous system neoplasm	3.45e-05	0.000206	CcSEcCtD
Imatinib—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	3.43e-05	0.000205	CcSEcCtD
Imatinib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	3.42e-05	0.000204	CcSEcCtD
Imatinib—Weight increased—Doxorubicin—peripheral nervous system neoplasm	3.42e-05	0.000204	CcSEcCtD
Imatinib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	3.41e-05	0.000204	CcSEcCtD
Imatinib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	3.4e-05	0.000203	CcSEcCtD
Imatinib—Sinusitis—Epirubicin—peripheral nervous system neoplasm	3.39e-05	0.000203	CcSEcCtD
Imatinib—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	3.39e-05	0.000203	CcSEcCtD
Imatinib—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	3.39e-05	0.000202	CcSEcCtD
Imatinib—Nausea—Dactinomycin—peripheral nervous system neoplasm	3.38e-05	0.000202	CcSEcCtD
Imatinib—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	3.37e-05	0.000202	CcSEcCtD
Imatinib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	3.37e-05	0.000201	CcSEcCtD
Imatinib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	3.36e-05	0.000201	CcSEcCtD
Imatinib—Dizziness—Vincristine—peripheral nervous system neoplasm	3.36e-05	0.000201	CcSEcCtD
Imatinib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	3.35e-05	0.0002	CcSEcCtD
Imatinib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	3.35e-05	0.0002	CcSEcCtD
Imatinib—Infestation—Doxorubicin—peripheral nervous system neoplasm	3.35e-05	0.0002	CcSEcCtD
Imatinib—Rash—Alitretinoin—peripheral nervous system neoplasm	3.32e-05	0.000199	CcSEcCtD
Imatinib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	3.32e-05	0.000198	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	3.32e-05	0.000198	CcSEcCtD
Imatinib—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	3.31e-05	0.000198	CcSEcCtD
Imatinib—Headache—Alitretinoin—peripheral nervous system neoplasm	3.3e-05	0.000197	CcSEcCtD
Imatinib—Renal failure—Doxorubicin—peripheral nervous system neoplasm	3.29e-05	0.000196	CcSEcCtD
Imatinib—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	3.28e-05	0.000196	CcSEcCtD
Imatinib—Urticaria—Etoposide—peripheral nervous system neoplasm	3.27e-05	0.000195	CcSEcCtD
Imatinib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	3.26e-05	0.000195	CcSEcCtD
Imatinib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	3.26e-05	0.000195	CcSEcCtD
Imatinib—Jaundice—Doxorubicin—peripheral nervous system neoplasm	3.26e-05	0.000195	CcSEcCtD
Imatinib—Rhinitis—Epirubicin—peripheral nervous system neoplasm	3.25e-05	0.000194	CcSEcCtD
Imatinib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	3.25e-05	0.000194	CcSEcCtD
Imatinib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	3.25e-05	0.000194	CcSEcCtD
Imatinib—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	3.25e-05	0.000194	CcSEcCtD
Imatinib—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	3.25e-05	0.000194	CcSEcCtD
Imatinib—Hepatitis—Epirubicin—peripheral nervous system neoplasm	3.25e-05	0.000194	CcSEcCtD
Imatinib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	3.25e-05	0.000194	CcSEcCtD
Imatinib—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	3.23e-05	0.000193	CcSEcCtD
Imatinib—Vomiting—Vincristine—peripheral nervous system neoplasm	3.23e-05	0.000193	CcSEcCtD
Imatinib—Asthenia—Cisplatin—peripheral nervous system neoplasm	3.22e-05	0.000192	CcSEcCtD
Imatinib—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	3.22e-05	0.000192	CcSEcCtD
Imatinib—Sweating—Doxorubicin—peripheral nervous system neoplasm	3.21e-05	0.000192	CcSEcCtD
Imatinib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	3.21e-05	0.000191	CcSEcCtD
Imatinib—Rash—Vincristine—peripheral nervous system neoplasm	3.2e-05	0.000191	CcSEcCtD
Imatinib—Dermatitis—Vincristine—peripheral nervous system neoplasm	3.2e-05	0.000191	CcSEcCtD
Imatinib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	3.2e-05	0.000191	CcSEcCtD
Imatinib—Haematuria—Doxorubicin—peripheral nervous system neoplasm	3.19e-05	0.000191	CcSEcCtD
Imatinib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000191	CcSEcCtD
Imatinib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	3.18e-05	0.00019	CcSEcCtD
Imatinib—Headache—Vincristine—peripheral nervous system neoplasm	3.18e-05	0.00019	CcSEcCtD
Imatinib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	3.16e-05	0.000189	CcSEcCtD
Imatinib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	3.16e-05	0.000189	CcSEcCtD
Imatinib—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	3.14e-05	0.000187	CcSEcCtD
Imatinib—Nausea—Alitretinoin—peripheral nervous system neoplasm	3.13e-05	0.000187	CcSEcCtD
Imatinib—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	3.12e-05	0.000187	CcSEcCtD
Imatinib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	3.07e-05	0.000184	CcSEcCtD
Imatinib—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	3.07e-05	0.000183	CcSEcCtD
Imatinib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	3.03e-05	0.000181	CcSEcCtD
Imatinib—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	3.03e-05	0.000181	CcSEcCtD
Imatinib—Tinnitus—Epirubicin—peripheral nervous system neoplasm	3.03e-05	0.000181	CcSEcCtD
Imatinib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	3.02e-05	0.00018	CcSEcCtD
Imatinib—Nausea—Vincristine—peripheral nervous system neoplasm	3.02e-05	0.00018	CcSEcCtD
Imatinib—Flushing—Epirubicin—peripheral nervous system neoplasm	3.01e-05	0.00018	CcSEcCtD
Imatinib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	3.01e-05	0.00018	CcSEcCtD
Imatinib—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	3.01e-05	0.00018	CcSEcCtD
Imatinib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	3e-05	0.000179	CcSEcCtD
Imatinib—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	3e-05	0.000179	CcSEcCtD
Imatinib—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	2.99e-05	0.000179	CcSEcCtD
Imatinib—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	2.98e-05	0.000178	CcSEcCtD
Imatinib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	2.97e-05	0.000177	CcSEcCtD
Imatinib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	2.96e-05	0.000177	CcSEcCtD
Imatinib—Asthenia—Etoposide—peripheral nervous system neoplasm	2.95e-05	0.000176	CcSEcCtD
Imatinib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	0.000176	CcSEcCtD
Imatinib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	2.95e-05	0.000176	CcSEcCtD
Imatinib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	2.94e-05	0.000176	CcSEcCtD
Imatinib—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	2.93e-05	0.000175	CcSEcCtD
Imatinib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	2.93e-05	0.000175	CcSEcCtD
Imatinib—Chills—Epirubicin—peripheral nervous system neoplasm	2.91e-05	0.000174	CcSEcCtD
Imatinib—Pruritus—Etoposide—peripheral nervous system neoplasm	2.91e-05	0.000174	CcSEcCtD
Imatinib—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	2.9e-05	0.000173	CcSEcCtD
Imatinib—Alopecia—Epirubicin—peripheral nervous system neoplasm	2.87e-05	0.000171	CcSEcCtD
Imatinib—Vomiting—Cisplatin—peripheral nervous system neoplasm	2.86e-05	0.000171	CcSEcCtD
Imatinib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	2.84e-05	0.00017	CcSEcCtD
Imatinib—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	2.84e-05	0.00017	CcSEcCtD
Imatinib—Rash—Cisplatin—peripheral nervous system neoplasm	2.83e-05	0.000169	CcSEcCtD
Imatinib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	2.83e-05	0.000169	CcSEcCtD
Imatinib—Erythema—Epirubicin—peripheral nervous system neoplasm	2.83e-05	0.000169	CcSEcCtD
Imatinib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	2.83e-05	0.000169	CcSEcCtD
Imatinib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	2.82e-05	0.000168	CcSEcCtD
Imatinib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	2.81e-05	0.000168	CcSEcCtD
Imatinib—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	2.8e-05	0.000167	CcSEcCtD
Imatinib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	2.79e-05	0.000167	CcSEcCtD
Imatinib—Flushing—Doxorubicin—peripheral nervous system neoplasm	2.79e-05	0.000167	CcSEcCtD
Imatinib—Flatulence—Epirubicin—peripheral nervous system neoplasm	2.78e-05	0.000166	CcSEcCtD
Imatinib—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	2.77e-05	0.000165	CcSEcCtD
Imatinib—Back pain—Epirubicin—peripheral nervous system neoplasm	2.73e-05	0.000163	CcSEcCtD
Imatinib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	2.73e-05	0.000163	CcSEcCtD
Imatinib—Dizziness—Etoposide—peripheral nervous system neoplasm	2.72e-05	0.000163	CcSEcCtD
Imatinib—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	2.72e-05	0.000162	CcSEcCtD
Imatinib—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	2.71e-05	0.000162	CcSEcCtD
Imatinib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	2.71e-05	0.000162	CcSEcCtD
Imatinib—Chills—Doxorubicin—peripheral nervous system neoplasm	2.7e-05	0.000161	CcSEcCtD
Imatinib—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	2.68e-05	0.00016	CcSEcCtD
Imatinib—Nausea—Cisplatin—peripheral nervous system neoplasm	2.67e-05	0.000159	CcSEcCtD
Imatinib—Vision blurred—Epirubicin—peripheral nervous system neoplasm	2.66e-05	0.000159	CcSEcCtD
Imatinib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	2.65e-05	0.000159	CcSEcCtD
Imatinib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	2.63e-05	0.000157	CcSEcCtD
Imatinib—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	2.62e-05	0.000157	CcSEcCtD
Imatinib—Vomiting—Etoposide—peripheral nervous system neoplasm	2.62e-05	0.000156	CcSEcCtD
Imatinib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	2.61e-05	0.000156	CcSEcCtD
Imatinib—Erythema—Doxorubicin—peripheral nervous system neoplasm	2.61e-05	0.000156	CcSEcCtD
Imatinib—Anaemia—Epirubicin—peripheral nervous system neoplasm	2.61e-05	0.000156	CcSEcCtD
Imatinib—Rash—Etoposide—peripheral nervous system neoplasm	2.59e-05	0.000155	CcSEcCtD
Imatinib—Dermatitis—Etoposide—peripheral nervous system neoplasm	2.59e-05	0.000155	CcSEcCtD
Imatinib—Headache—Etoposide—peripheral nervous system neoplasm	2.58e-05	0.000154	CcSEcCtD
Imatinib—Flatulence—Doxorubicin—peripheral nervous system neoplasm	2.58e-05	0.000154	CcSEcCtD
Imatinib—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	2.56e-05	0.000153	CcSEcCtD
Imatinib—Malaise—Epirubicin—peripheral nervous system neoplasm	2.55e-05	0.000152	CcSEcCtD
Imatinib—Vertigo—Epirubicin—peripheral nervous system neoplasm	2.54e-05	0.000152	CcSEcCtD
Imatinib—Syncope—Epirubicin—peripheral nervous system neoplasm	2.53e-05	0.000151	CcSEcCtD
Imatinib—Leukopenia—Epirubicin—peripheral nervous system neoplasm	2.53e-05	0.000151	CcSEcCtD
Imatinib—Back pain—Doxorubicin—peripheral nervous system neoplasm	2.53e-05	0.000151	CcSEcCtD
Imatinib—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	2.51e-05	0.00015	CcSEcCtD
Imatinib—Palpitations—Epirubicin—peripheral nervous system neoplasm	2.5e-05	0.000149	CcSEcCtD
Imatinib—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	2.48e-05	0.000148	CcSEcCtD
Imatinib—Cough—Epirubicin—peripheral nervous system neoplasm	2.47e-05	0.000147	CcSEcCtD
Imatinib—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	2.46e-05	0.000147	CcSEcCtD
Imatinib—Convulsion—Epirubicin—peripheral nervous system neoplasm	2.45e-05	0.000146	CcSEcCtD
Imatinib—Nausea—Etoposide—peripheral nervous system neoplasm	2.44e-05	0.000146	CcSEcCtD
Imatinib—Hypertension—Epirubicin—peripheral nervous system neoplasm	2.44e-05	0.000146	CcSEcCtD
Imatinib—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	2.43e-05	0.000145	CcSEcCtD
Imatinib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	2.42e-05	0.000144	CcSEcCtD
Imatinib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	2.41e-05	0.000144	CcSEcCtD
Imatinib—Chest pain—Epirubicin—peripheral nervous system neoplasm	2.41e-05	0.000144	CcSEcCtD
Imatinib—Myalgia—Epirubicin—peripheral nervous system neoplasm	2.41e-05	0.000144	CcSEcCtD
Imatinib—Anxiety—Epirubicin—peripheral nervous system neoplasm	2.4e-05	0.000143	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	2.39e-05	0.000143	CcSEcCtD
Imatinib—Discomfort—Epirubicin—peripheral nervous system neoplasm	2.38e-05	0.000142	CcSEcCtD
Imatinib—Malaise—Doxorubicin—peripheral nervous system neoplasm	2.36e-05	0.000141	CcSEcCtD
Imatinib—Dry mouth—Epirubicin—peripheral nervous system neoplasm	2.35e-05	0.000141	CcSEcCtD
Imatinib—Vertigo—Doxorubicin—peripheral nervous system neoplasm	2.35e-05	0.00014	CcSEcCtD
Imatinib—Syncope—Doxorubicin—peripheral nervous system neoplasm	2.34e-05	0.00014	CcSEcCtD
Imatinib—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	2.34e-05	0.00014	CcSEcCtD
Imatinib—Confusional state—Epirubicin—peripheral nervous system neoplasm	2.33e-05	0.000139	CcSEcCtD
Imatinib—Palpitations—Doxorubicin—peripheral nervous system neoplasm	2.31e-05	0.000138	CcSEcCtD
Imatinib—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	2.31e-05	0.000138	CcSEcCtD
Imatinib—Oedema—Epirubicin—peripheral nervous system neoplasm	2.31e-05	0.000138	CcSEcCtD
Imatinib—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	2.3e-05	0.000137	CcSEcCtD
Imatinib—Infection—Epirubicin—peripheral nervous system neoplasm	2.29e-05	0.000137	CcSEcCtD
Imatinib—Cough—Doxorubicin—peripheral nervous system neoplasm	2.28e-05	0.000136	CcSEcCtD
Imatinib—Shock—Epirubicin—peripheral nervous system neoplasm	2.27e-05	0.000136	CcSEcCtD
Imatinib—Convulsion—Doxorubicin—peripheral nervous system neoplasm	2.27e-05	0.000135	CcSEcCtD
Imatinib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	2.26e-05	0.000135	CcSEcCtD
Imatinib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	2.26e-05	0.000135	CcSEcCtD
Imatinib—Hypertension—Doxorubicin—peripheral nervous system neoplasm	2.26e-05	0.000135	CcSEcCtD
Imatinib—Tachycardia—Epirubicin—peripheral nervous system neoplasm	2.25e-05	0.000134	CcSEcCtD
Imatinib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	2.24e-05	0.000134	CcSEcCtD
Imatinib—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	2.23e-05	0.000133	CcSEcCtD
Imatinib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	2.23e-05	0.000133	CcSEcCtD
Imatinib—Chest pain—Doxorubicin—peripheral nervous system neoplasm	2.23e-05	0.000133	CcSEcCtD
Imatinib—Myalgia—Doxorubicin—peripheral nervous system neoplasm	2.23e-05	0.000133	CcSEcCtD
Imatinib—Anxiety—Doxorubicin—peripheral nervous system neoplasm	2.22e-05	0.000133	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	2.21e-05	0.000132	CcSEcCtD
Imatinib—Discomfort—Doxorubicin—peripheral nervous system neoplasm	2.2e-05	0.000131	CcSEcCtD
Imatinib—Anorexia—Epirubicin—peripheral nervous system neoplasm	2.2e-05	0.000131	CcSEcCtD
Imatinib—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	2.18e-05	0.00013	CcSEcCtD
Imatinib—Hypotension—Epirubicin—peripheral nervous system neoplasm	2.16e-05	0.000129	CcSEcCtD
Imatinib—Confusional state—Doxorubicin—peripheral nervous system neoplasm	2.15e-05	0.000129	CcSEcCtD
Imatinib—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	2.13e-05	0.000127	CcSEcCtD
Imatinib—Oedema—Doxorubicin—peripheral nervous system neoplasm	2.13e-05	0.000127	CcSEcCtD
Imatinib—Infection—Doxorubicin—peripheral nervous system neoplasm	2.12e-05	0.000127	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	2.1e-05	0.000126	CcSEcCtD
Imatinib—Shock—Doxorubicin—peripheral nervous system neoplasm	2.1e-05	0.000125	CcSEcCtD
Imatinib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	2.09e-05	0.000125	CcSEcCtD
Imatinib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	2.09e-05	0.000125	CcSEcCtD
Imatinib—Insomnia—Epirubicin—peripheral nervous system neoplasm	2.09e-05	0.000125	CcSEcCtD
Imatinib—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	2.08e-05	0.000124	CcSEcCtD
Imatinib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	2.07e-05	0.000124	CcSEcCtD
Imatinib—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	2.07e-05	0.000124	CcSEcCtD
Imatinib—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	2.06e-05	0.000123	CcSEcCtD
Imatinib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	2.06e-05	0.000123	CcSEcCtD
Imatinib—Somnolence—Epirubicin—peripheral nervous system neoplasm	2.05e-05	0.000122	CcSEcCtD
Imatinib—Anorexia—Doxorubicin—peripheral nervous system neoplasm	2.03e-05	0.000121	CcSEcCtD
Imatinib—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	2.03e-05	0.000121	CcSEcCtD
Imatinib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	2e-05	0.00012	CcSEcCtD
Imatinib—Hypotension—Doxorubicin—peripheral nervous system neoplasm	1.99e-05	0.000119	CcSEcCtD
Imatinib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	1.99e-05	0.000119	CcSEcCtD
Imatinib—Fatigue—Epirubicin—peripheral nervous system neoplasm	1.99e-05	0.000119	CcSEcCtD
Imatinib—Pain—Epirubicin—peripheral nervous system neoplasm	1.97e-05	0.000118	CcSEcCtD
Imatinib—Constipation—Epirubicin—peripheral nervous system neoplasm	1.97e-05	0.000118	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	1.94e-05	0.000116	CcSEcCtD
Imatinib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	1.93e-05	0.000115	CcSEcCtD
Imatinib—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	1.92e-05	0.000114	CcSEcCtD
Imatinib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	1.9e-05	0.000114	CcSEcCtD
Imatinib—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	1.9e-05	0.000114	CcSEcCtD
Imatinib—Somnolence—Doxorubicin—peripheral nervous system neoplasm	1.9e-05	0.000113	CcSEcCtD
Imatinib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	1.89e-05	0.000113	CcSEcCtD
Imatinib—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	1.88e-05	0.000112	CcSEcCtD
Imatinib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	1.86e-05	0.000111	CcSEcCtD
Imatinib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	1.84e-05	0.00011	CcSEcCtD
Imatinib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	1.84e-05	0.00011	CcSEcCtD
Imatinib—Urticaria—Epirubicin—peripheral nervous system neoplasm	1.83e-05	0.000109	CcSEcCtD
Imatinib—Pain—Doxorubicin—peripheral nervous system neoplasm	1.82e-05	0.000109	CcSEcCtD
Imatinib—Constipation—Doxorubicin—peripheral nervous system neoplasm	1.82e-05	0.000109	CcSEcCtD
Imatinib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	1.82e-05	0.000109	CcSEcCtD
Imatinib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	1.82e-05	0.000109	CcSEcCtD
Imatinib—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	1.76e-05	0.000105	CcSEcCtD
Imatinib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	1.75e-05	0.000104	CcSEcCtD
Imatinib—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	1.7e-05	0.000101	CcSEcCtD
Imatinib—Urticaria—Doxorubicin—peripheral nervous system neoplasm	1.7e-05	0.000101	CcSEcCtD
Imatinib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	1.69e-05	0.000101	CcSEcCtD
Imatinib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	1.69e-05	0.000101	CcSEcCtD
Imatinib—Asthenia—Epirubicin—peripheral nervous system neoplasm	1.65e-05	9.88e-05	CcSEcCtD
Imatinib—Pruritus—Epirubicin—peripheral nervous system neoplasm	1.63e-05	9.75e-05	CcSEcCtD
Imatinib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	1.58e-05	9.43e-05	CcSEcCtD
Imatinib—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	1.57e-05	9.39e-05	CcSEcCtD
Imatinib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	1.53e-05	9.15e-05	CcSEcCtD
Imatinib—Dizziness—Epirubicin—peripheral nervous system neoplasm	1.53e-05	9.11e-05	CcSEcCtD
Imatinib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	1.51e-05	9.02e-05	CcSEcCtD
Imatinib—Vomiting—Epirubicin—peripheral nervous system neoplasm	1.47e-05	8.76e-05	CcSEcCtD
Imatinib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	1.46e-05	8.72e-05	CcSEcCtD
Imatinib—Rash—Epirubicin—peripheral nervous system neoplasm	1.45e-05	8.69e-05	CcSEcCtD
Imatinib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	1.45e-05	8.68e-05	CcSEcCtD
Imatinib—Headache—Epirubicin—peripheral nervous system neoplasm	1.44e-05	8.63e-05	CcSEcCtD
Imatinib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	1.41e-05	8.43e-05	CcSEcCtD
Imatinib—Nausea—Epirubicin—peripheral nervous system neoplasm	1.37e-05	8.18e-05	CcSEcCtD
Imatinib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	1.36e-05	8.1e-05	CcSEcCtD
Imatinib—Rash—Doxorubicin—peripheral nervous system neoplasm	1.35e-05	8.04e-05	CcSEcCtD
Imatinib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	1.34e-05	8.03e-05	CcSEcCtD
Imatinib—Headache—Doxorubicin—peripheral nervous system neoplasm	1.34e-05	7.99e-05	CcSEcCtD
Imatinib—Nausea—Doxorubicin—peripheral nervous system neoplasm	1.27e-05	7.57e-05	CcSEcCtD
Imatinib—PDGFRA—Immune System—PTPN11—peripheral nervous system neoplasm	8.5e-06	0.000121	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	8.42e-06	0.00012	CbGpPWpGaD
Imatinib—LCK—Immune System—HGF—peripheral nervous system neoplasm	8.42e-06	0.00012	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	8.41e-06	0.000119	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	8.36e-06	0.000119	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—GNAS—peripheral nervous system neoplasm	8.35e-06	0.000119	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—ERBB2—peripheral nervous system neoplasm	8.34e-06	0.000118	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—BCHE—peripheral nervous system neoplasm	8.29e-06	0.000118	CbGpPWpGaD
Imatinib—KIT—Disease—PTPN11—peripheral nervous system neoplasm	8.29e-06	0.000118	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—HRAS—peripheral nervous system neoplasm	8.27e-06	0.000118	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	8.23e-06	0.000117	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.23e-06	0.000117	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	8.16e-06	0.000116	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.16e-06	0.000116	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.14e-06	0.000116	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KNG1—peripheral nervous system neoplasm	8.14e-06	0.000116	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—HRAS—peripheral nervous system neoplasm	8.13e-06	0.000116	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—TH—peripheral nervous system neoplasm	8.11e-06	0.000115	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—TH—peripheral nervous system neoplasm	8.04e-06	0.000114	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—TH—peripheral nervous system neoplasm	8.03e-06	0.000114	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	8e-06	0.000114	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—BCHE—peripheral nervous system neoplasm	7.96e-06	0.000113	CbGpPWpGaD
Imatinib—SLC22A2—Neuronal System—HRAS—peripheral nervous system neoplasm	7.95e-06	0.000113	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	7.92e-06	0.000113	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.92e-06	0.000113	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.91e-06	0.000112	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—GNAS—peripheral nervous system neoplasm	7.9e-06	0.000112	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—NRAS—peripheral nervous system neoplasm	7.9e-06	0.000112	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	7.85e-06	0.000112	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PTPN11—peripheral nervous system neoplasm	7.84e-06	0.000111	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—TH—peripheral nervous system neoplasm	7.79e-06	0.000111	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	7.76e-06	0.00011	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	7.76e-06	0.00011	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—NRAS—peripheral nervous system neoplasm	7.7e-06	0.000109	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—PTPN11—peripheral nervous system neoplasm	7.65e-06	0.000109	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	7.64e-06	0.000109	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	7.64e-06	0.000109	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.59e-06	0.000108	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	7.59e-06	0.000108	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	7.49e-06	0.000106	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—TH—peripheral nervous system neoplasm	7.48e-06	0.000106	CbGpPWpGaD
Imatinib—ABL1—Immune System—PTPN11—peripheral nervous system neoplasm	7.46e-06	0.000106	CbGpPWpGaD
Imatinib—SLC22A1—Neuronal System—HRAS—peripheral nervous system neoplasm	7.41e-06	0.000105	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ENO2—peripheral nervous system neoplasm	7.32e-06	0.000104	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	7.27e-06	0.000103	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—AKT1—peripheral nervous system neoplasm	7.18e-06	0.000102	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—GNAS—peripheral nervous system neoplasm	7.12e-06	0.000101	CbGpPWpGaD
Imatinib—KIT—Immune System—ERBB2—peripheral nervous system neoplasm	7.09e-06	0.000101	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PTPN11—peripheral nervous system neoplasm	7.07e-06	0.0001	CbGpPWpGaD
Imatinib—LCK—Hemostasis—NRAS—peripheral nervous system neoplasm	7.04e-06	0.0001	CbGpPWpGaD
Imatinib—ALB—Hemostasis—PTPN11—peripheral nervous system neoplasm	7e-06	9.95e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	6.97e-06	9.91e-05	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—HRAS—peripheral nervous system neoplasm	6.78e-06	9.63e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—ERBB2—peripheral nervous system neoplasm	6.72e-06	9.54e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	6.71e-06	9.54e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	6.62e-06	9.41e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—GNAS—peripheral nervous system neoplasm	6.56e-06	9.32e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—GNAS—peripheral nervous system neoplasm	6.55e-06	9.31e-05	CbGpPWpGaD
Imatinib—KIT—Disease—ERBB2—peripheral nervous system neoplasm	6.55e-06	9.31e-05	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TP53—peripheral nervous system neoplasm	6.54e-06	9.3e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KNG1—peripheral nervous system neoplasm	6.54e-06	9.29e-05	CbGpPWpGaD
Imatinib—CA14—Metabolism—AKT1—peripheral nervous system neoplasm	6.51e-06	9.25e-05	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	6.51e-06	9.25e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	6.5e-06	9.23e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—ABCB1—peripheral nervous system neoplasm	6.44e-06	9.15e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—ABCB1—peripheral nervous system neoplasm	6.43e-06	9.14e-05	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—HRAS—peripheral nervous system neoplasm	6.42e-06	9.12e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—HRAS—peripheral nervous system neoplasm	6.38e-06	9.06e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—GNAS—peripheral nervous system neoplasm	6.36e-06	9.04e-05	CbGpPWpGaD
Imatinib—CA6—Metabolism—AKT1—peripheral nervous system neoplasm	6.35e-06	9.01e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—NRAS—peripheral nervous system neoplasm	6.34e-06	9.01e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—ENO2—peripheral nervous system neoplasm	6.3e-06	8.95e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.26e-06	8.89e-05	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—HRAS—peripheral nervous system neoplasm	6.26e-06	8.89e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—ABCB1—peripheral nervous system neoplasm	6.24e-06	8.87e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	6.23e-06	8.85e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—ERBB2—peripheral nervous system neoplasm	6.2e-06	8.81e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	6.18e-06	8.78e-05	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	6.16e-06	8.75e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	6.15e-06	8.74e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PTPN11—peripheral nervous system neoplasm	6.14e-06	8.73e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—GNAS—peripheral nervous system neoplasm	6.11e-06	8.68e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	6.09e-06	8.65e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—ERBB2—peripheral nervous system neoplasm	6.05e-06	8.59e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ABCB1—peripheral nervous system neoplasm	5.99e-06	8.51e-05	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.99e-06	8.5e-05	CbGpPWpGaD
Imatinib—CA7—Metabolism—AKT1—peripheral nervous system neoplasm	5.92e-06	8.42e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.9e-06	8.38e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—ERBB2—peripheral nervous system neoplasm	5.9e-06	8.38e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	5.81e-06	8.26e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.8e-06	8.24e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.78e-06	8.21e-05	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.75e-06	8.17e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.72e-06	8.12e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.68e-06	8.07e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTPN11—peripheral nervous system neoplasm	5.67e-06	8.06e-05	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.67e-06	8.05e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	5.66e-06	8.03e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.63e-06	8e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—AKT1—peripheral nervous system neoplasm	5.63e-06	8e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	5.61e-06	7.97e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—ERBB2—peripheral nervous system neoplasm	5.59e-06	7.94e-05	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	5.55e-06	7.89e-05	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—AKT1—peripheral nervous system neoplasm	5.53e-06	7.85e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	5.52e-06	7.84e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.49e-06	7.8e-05	CbGpPWpGaD
Imatinib—CA12—Metabolism—AKT1—peripheral nervous system neoplasm	5.49e-06	7.8e-05	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.44e-06	7.73e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—NRAS—peripheral nervous system neoplasm	5.4e-06	7.67e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TP53—peripheral nervous system neoplasm	5.39e-06	7.66e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	5.38e-06	7.65e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—BCHE—peripheral nervous system neoplasm	5.32e-06	7.56e-05	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	5.28e-06	7.5e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	5.2e-06	7.39e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	5.2e-06	7.38e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	5.18e-06	7.36e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	5.16e-06	7.33e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—HRAS—peripheral nervous system neoplasm	5.15e-06	7.32e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—NRAS—peripheral nervous system neoplasm	5.11e-06	7.26e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.1e-06	7.25e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.08e-06	7.21e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—TH—peripheral nervous system neoplasm	5e-06	7.11e-05	CbGpPWpGaD
Imatinib—KIT—Disease—NRAS—peripheral nervous system neoplasm	4.98e-06	7.08e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—AKT1—peripheral nervous system neoplasm	4.97e-06	7.07e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.95e-06	7.03e-05	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	4.9e-06	6.96e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—ERBB2—peripheral nervous system neoplasm	4.85e-06	6.9e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	4.78e-06	6.79e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.76e-06	6.77e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	4.74e-06	6.74e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—NRAS—peripheral nervous system neoplasm	4.72e-06	6.7e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	4.66e-06	6.63e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	4.66e-06	6.61e-05	CbGpPWpGaD
Imatinib—KIT—Disease—MYC—peripheral nervous system neoplasm	4.64e-06	6.59e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—HRAS—peripheral nervous system neoplasm	4.64e-06	6.59e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—NRAS—peripheral nervous system neoplasm	4.6e-06	6.54e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.59e-06	6.52e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.56e-06	6.48e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—AKT1—peripheral nervous system neoplasm	4.55e-06	6.46e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	4.49e-06	6.38e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—NRAS—peripheral nervous system neoplasm	4.49e-06	6.37e-05	CbGpPWpGaD
Imatinib—LCK—Disease—ERBB2—peripheral nervous system neoplasm	4.48e-06	6.37e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	4.46e-06	6.33e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.45e-06	6.32e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.44e-06	6.3e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	4.41e-06	6.26e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	4.4e-06	6.24e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MYC—peripheral nervous system neoplasm	4.39e-06	6.24e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	4.39e-06	6.23e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	4.36e-06	6.19e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.34e-06	6.17e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—NRAS—peripheral nervous system neoplasm	4.25e-06	6.04e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—NRAS—peripheral nervous system neoplasm	4.21e-06	5.98e-05	CbGpPWpGaD
Imatinib—CA2—Metabolism—AKT1—peripheral nervous system neoplasm	4.2e-06	5.96e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.19e-06	5.96e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.16e-06	5.91e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.16e-06	5.91e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	4.13e-06	5.87e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	4.1e-06	5.82e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—AKT1—peripheral nervous system neoplasm	4.1e-06	5.82e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GNAS—peripheral nervous system neoplasm	4.09e-06	5.8e-05	CbGpPWpGaD
Imatinib—CA1—Metabolism—AKT1—peripheral nervous system neoplasm	4.02e-06	5.71e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—ABCB1—peripheral nervous system neoplasm	4.01e-06	5.7e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.97e-06	5.64e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MYC—peripheral nervous system neoplasm	3.96e-06	5.62e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—HRAS—peripheral nervous system neoplasm	3.95e-06	5.61e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.94e-06	5.6e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	3.93e-06	5.59e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.91e-06	5.56e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HRAS—peripheral nervous system neoplasm	3.74e-06	5.31e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	3.72e-06	5.29e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—NRAS—peripheral nervous system neoplasm	3.69e-06	5.25e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	3.67e-06	5.21e-05	CbGpPWpGaD
Imatinib—KIT—Disease—HRAS—peripheral nervous system neoplasm	3.65e-06	5.18e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.64e-06	5.18e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	3.6e-06	5.11e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	3.58e-06	5.09e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.55e-06	5.05e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.55e-06	5.04e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—AKT1—peripheral nervous system neoplasm	3.54e-06	5.02e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	3.5e-06	4.97e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.49e-06	4.96e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—AKT1—peripheral nervous system neoplasm	3.49e-06	4.95e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.48e-06	4.95e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HRAS—peripheral nervous system neoplasm	3.45e-06	4.9e-05	CbGpPWpGaD
Imatinib—LCK—Disease—NRAS—peripheral nervous system neoplasm	3.41e-06	4.84e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	3.4e-06	4.83e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	3.37e-06	4.79e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HRAS—peripheral nervous system neoplasm	3.37e-06	4.78e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	3.34e-06	4.75e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	3.31e-06	4.7e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.3e-06	4.69e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—AKT1—peripheral nervous system neoplasm	3.3e-06	4.69e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	3.28e-06	4.66e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—HRAS—peripheral nervous system neoplasm	3.28e-06	4.66e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.25e-06	4.62e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—peripheral nervous system neoplasm	3.22e-06	4.58e-05	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—peripheral nervous system neoplasm	3.22e-06	4.57e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—peripheral nervous system neoplasm	3.18e-06	4.51e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.14e-06	4.46e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HRAS—peripheral nervous system neoplasm	3.11e-06	4.42e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—HRAS—peripheral nervous system neoplasm	3.08e-06	4.38e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.08e-06	4.37e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.08e-06	4.37e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—peripheral nervous system neoplasm	3.05e-06	4.33e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.98e-06	4.23e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—peripheral nervous system neoplasm	2.97e-06	4.22e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—peripheral nervous system neoplasm	2.9e-06	4.12e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	2.87e-06	4.08e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	2.86e-06	4.06e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.85e-06	4.05e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	2.8e-06	3.98e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.77e-06	3.94e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—peripheral nervous system neoplasm	2.75e-06	3.9e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.74e-06	3.89e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—peripheral nervous system neoplasm	2.72e-06	3.86e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—HRAS—peripheral nervous system neoplasm	2.7e-06	3.84e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	2.7e-06	3.84e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.67e-06	3.79e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.55e-06	3.63e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.53e-06	3.59e-05	CbGpPWpGaD
Imatinib—LCK—Disease—HRAS—peripheral nervous system neoplasm	2.49e-06	3.54e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.42e-06	3.43e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.39e-06	3.39e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—peripheral nervous system neoplasm	2.39e-06	3.39e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.28e-06	3.23e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.25e-06	3.2e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.22e-06	3.16e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	2.21e-06	3.13e-05	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—peripheral nervous system neoplasm	2.2e-06	3.13e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.18e-06	3.09e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	2.16e-06	3.07e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.13e-06	3.03e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.92e-06	2.73e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.83e-06	2.6e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	1.79e-06	2.54e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—peripheral nervous system neoplasm	1.77e-06	2.52e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—peripheral nervous system neoplasm	1.77e-06	2.51e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.75e-06	2.48e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—peripheral nervous system neoplasm	1.72e-06	2.44e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—peripheral nervous system neoplasm	1.65e-06	2.34e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.54e-06	2.19e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	1.28e-06	1.82e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—peripheral nervous system neoplasm	1.1e-06	1.57e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	9.9e-07	1.41e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	9.66e-07	1.37e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	9.11e-07	1.29e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	9.03e-07	1.28e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	7.71e-07	1.1e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	5.95e-07	8.46e-06	CbGpPWpGaD
